|
Novo Nordisk’s CagriSema Falls Short of Weight Loss Expectations in REDEFINE 2 Trial
|
Written by: J. Smith |
Hits: 625
|
|
Novo Nordisk Launches $499 Cash Program for Wegovy, Matching Eli Lilly’s Zepbound Pricing
|
Written by: J. Smith |
Hits: 577
|
|
Lilly Prepares for High Demand With $550M Stockpile of Oral GLP-1
|
Written by: J. Smith |
Hits: 444
|
|
Dexcom G7 Supply Disruptions
|
Written by: J. Smith |
Hits: 1189
|
|
Tandem Diabetes Care Secures FDA Clearance for Control-IQ+ in Type 2 Diabetes
|
Written by: J. Smith |
Hits: 875
|
|
Compounders Sue FDA Over Semaglutide Shortage Decision
|
Written by: J. Smith |
Hits: 786
|
|
Lilly Expands Zepbound Vial Options, Lowers Prices for Self-Pay Patients
|
Written by: J. Smith |
Hits: 870
|
|
FDA Warns Patients to Regularly Check Smartphone Alert Settings for Diabetes Devices
|
Written by: J. Smith |
Hits: 1120
|
|
FDA Approves Merilog, the First Rapid-Acting Insulin Biosimilar
|
Written by: J. Smith |
Hits: 878
|
|
FDA Declares Semaglutide Shortage Resolved, Raising Concerns Over Compounded Versions
|
Written by: J. Smith |
Hits: 735
|
